Risk of Periprosthetic Joint Infection After Intra-Articular Corticosteroid Injection Following Unicompartmental Knee Arthroplasty.

Autor: Rodriguez HC; Holy Cross Orthopedic Institute, Fort Lauderdale, Florida; Larkin Community Hospital, Department of Orthopaedic Surgery, South Miami, Florida., Mekkawy KL; Holy Cross Orthopedic Institute, Fort Lauderdale, Florida., Watkins A; Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania., Roche MW; Holy Cross Orthopedic Institute, Fort Lauderdale, Florida; Hospital for Special Surgery Florida, West Palm Beach, Florida., Burke WV; Holy Cross Orthopedic Institute, Fort Lauderdale, Florida., Gosthe RG; Holy Cross Orthopedic Institute, Fort Lauderdale, Florida.
Jazyk: angličtina
Zdroj: The Journal of arthroplasty [J Arthroplasty] 2023 May; Vol. 38 (5), pp. 815-819. Date of Electronic Publication: 2022 Dec 10.
DOI: 10.1016/j.arth.2022.12.005
Abstrakt: Background: Perioperative intra-articular joint injection is a known risk factor for developing prosthetic joint infection (PJI) in the immediate preoperative and postoperative periods for total knee arthroplasty, but is less defined in unicompartmental knee arthroplasty (UKA). The goal of this study was to elucidate the risk of developing PJI after intra-articular corticosteroid injection (IACI) into a post UKA knee.
Methods: A retrospective review of a nationwide administrative claims database was performed from January 2015 to October 2020. Patients who underwent UKA and had an ipsilateral IACI were identified and matched 2:1 to a control group of primary UKA patients who did not receive IACI. Multivariate logistic analyses were conducted to assess differences in PJI rates at 6 months, 1 year, and 2 years.
Results: A total of 47,903 cases were identified, of which 2,656 (5.5%) cases received IACI. The mean time from UKA to IACI was 355 days. The incidence of PJI in the IACI group was 2.7%, compared to 1.3% in the control group. The rate of PJI after IACI was significantly higher than the rate in the control group at 6 months, 1 year, and 2 years (all P < .05). The majority of PJI occurred within the first 6 months following IACI (75%).
Conclusion: In this study, IACI in a UKA doubled the risk of PJI compared to patients who did not receive an injection. Surgeons should be aware of this increased risk to aid in their decision-making about injecting into a UKA.
Level of Evidence: III, retrospective comparative study.
(Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: